Efficacy and safety of ASF-1096 Cream 0.5% in the treatment of patients with newly developed discoid lupus erythematosus (DLE) lesions. A multicentre clinical phase 2, placebo controlled and double blind proof of concept study.

Trial Profile

Efficacy and safety of ASF-1096 Cream 0.5% in the treatment of patients with newly developed discoid lupus erythematosus (DLE) lesions. A multicentre clinical phase 2, placebo controlled and double blind proof of concept study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Levosalbutamol (Primary)
  • Indications Discoid lupus erythematosus; Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top